# A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity

Study · id `cardio:ct-nct02280083` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02280083](<https://clinicaltrials.gov/study/NCT02280083>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02280083

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 180 participants.

## Technical summary

Registry record NCT02280083. Randomized; quadruple masking; primary purpose treatment. Start 2014-07 (registry gives no type); primary completion 2016-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 180 participants (enrolled count; ClinicalTrials.gov record NCT02280083, source copy `cardio:ctgov-nct02280083-2016-09-26`, retrieved 2026-10-26)
- Start date: 2014-07 (registry gives no type) (ClinicalTrials.gov record NCT02280083, source copy `cardio:ctgov-nct02280083-2016-09-26`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02280083, source copy `cardio:ctgov-nct02280083-2016-09-26`, retrieved 2026-10-26)
- Completion: 2016-09 (actual) (ClinicalTrials.gov record NCT02280083, source copy `cardio:ctgov-nct02280083-2016-09-26`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02280083-2016-09-26`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Botulinum Toxin Type A for Injection(HengLi®) in Subjects With Post-stroke Upper Limb Spasticity
- Condition: Cerebrovascular Accident
- Intervention (Drug): Botulinum Toxin Type A for Injection
- Intervention (Drug): placebo
- Lead sponsor: Lanzhou Institute of Biological Products Co., Ltd
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Stroke (`core:stroke`)

## Provenance

Content hash: 1b142bf7efe5ae006c5f5e78b1c51ac1ae485ddd30e0fa53a5ed147185be2afb
Last substantive edit: 2026-10-26
Evidence last checked: Not recorded
